Lead Partner: 

ICON plc is a global provider of clinical development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently, operates from 84 locations in 38 countries and has approximately 12,300 employees.


Senior Partner: 

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also developing its digital health and enterprise services.

Program Partner

Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.

From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.

Program Partner

Continuum Clinical is a global clinical trial enrollment company. With over twenty-five years of experience, Continuum Clinical specializes in providing sponsors and CROs with patient recruitment and retention planning, study and site support, patient recruitment campaigns, patient advocacy and diversity & inclusion services, retention solutions, and reporting and analytics.

hepquant logo
Program Partner

HepQuant-SHUNT, -STAT, and -FLOW are sensitive, reproducible, accurate, and minimally-invasive tests of global liver function and physiology. They target not only the liver but also the portal circulation and generate a Disease Severity Index (DSI), which ranges from 0 (healthy) to 50 (severe liver disease). DSI may be used for measuring severity of liver disease, tracking disease progression, and monitoring treatment effects. HepQuant’s services include study design, training, consultation, Test Kits, and Laboratory Analyses.

Program Partner

Kunming Biomed International (KBI) is a world leading CRO providing preclinical research services that specialized in nonhuman primates (NHPs).  Led by an experienced international team, KBI has collaborated with over 18 large pharmas using translational NHP models for pharmacological efficacy and safety evaluations, including NASH/fibrosis, diabetes and diabetic complications (nephropathy, retinopathy), and cardiovascular diseases (dyslipidemia, heart failure), etc.  KBI has state-of-the-art AAALAC accredited animal research facilities, and extensive colonies (>6000) of healthy and diseased models.

Program Partner

The Jackson Laboratory is the definitive resource for uncovering the genetic and molecular causes of genetic diseases. With ever-increasing precision, JAX® Mice, Clinical & Research Services provides the most innovative and unparalleled mouse models and research services, supporting the transition from discovery to application, resulting in individualized treatments and therapies.

crown bi logo
Spotlight Partner

CrownBio’s metabolic disease portfolio is a unique continuum of translational platforms that enable our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development. Our clients engage with these translational platforms, which include rodent and non-human primates, (NHP) to model human liver disease pathologies and use them to predict human efficacy and safety of therapeutic candidates.

Spotlight Partner

InfiCure Bio has developed a new and unique preclinical mouse model, the NIF mouse, which spontaneously develops fibrosis in multiple organs e.g. the liver and kidneys.  We offer expert led, tailored, high-quality drug validation services for R&D companies and CRO’s. Our unique whole organism model offers extraordinary research advantages; is 100 percent reproducible, has a pathological progress similar to humans and displays a fibrosis preceded by chronic inflammation. InfiCure Bio is ready to break the status quo in anti-fibrotic drug development.


Spotlight Partner

Perspectum® is a healthcare software company that uses state-of-the-art artificial intelligence, image analysis and physics to develop and commercialize innovative biomarkers for metabolic disease and cancer, delivered through software-as-a-service (SaaS). Perspectum has in-house capabilities covering the entire life cycle, driven by a world-leading team of clinicians, software engineers and scientists. LiverMultiScan®, is a proprietary, non-invasive, software-based solution that has proven utility and accuracy in stratifying and monitoring patients with liver disorders, including NASH. MRCP+ is the most advanced biliary visualization software available, allowing unprecedented quantitative assessment of the bile ducts, pancreatic duct and gall bladder in 3D.


Logo Physiogenex (002
Spotlight Partner

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications.

For >15 years, we have been evaluating the efficacy of our clients' drugs using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.

Spotlight Partner

The development of better medicine begins with better disease models. Unfortunately, current in vitro models poorly mimic the pathophysiology of fibrosis, leaving a major gap in compound screening and testing efforts in anti-fibrosis drug discovery. Xylyx Bio’s native, disease-specific extracellular matrix substrates allow drug candidates to be investigated in vitro in a disease-relevant environment, enabling cell models that are significantly more predictive of human pathophysiology. Xylyx Bio products comprise both the mechanical properties and complex ratios of ECM components specific and unique to each organ type and disease state and are available in a variety of 2D and 3D product formats to support high-throughput assays.

Breath-Biopsy-RGBAsset 1
Exhibition Partner

Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by breath-based diagnostics, through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.

Exhibition Partner

Visit Diapharma to discuss K18 assays as prescreening tools and secondary endpoints in NASH clinical trials. Learn about our panels of mechanistic biomarkers that provide insight into the biological processes occurring during liver injury. Keratin/Keratin 18 (CK18/K18) is an important biomarker of hepatocyte cell death. Explore M30/M65 ELISAs for measuring hepatocyte apoptosis/necrosis noninvasively. Diapharma offers additional assays for liver injury, including HA, α‐GST, and Collagen IV. For research use only in the U.S. and Canada.

Event Partner

Accelerated Enrollment Solutions (AES) is the new standard in clinical trial productivity. Our innovative and integrated site and patient services secure the success of clinical trials by providing enrollment, timing, and budget certainty. AES offers sponsors and contract research organizations best-in-class site conduct and patient access solutions, which include engaging, recruiting and retaining patients in clinical studies via a global network of dedicated research sites.


RCI_logo_horiz.TM2 (002)
Event Partner

Recombinetics (RCI) is a leader in the development and deployment of gene-editing solutions. Its disease model subsidiary, Surrogen, leverages RCI’s DNA tool kit and expertise to develop custom-tailored pig models that simulate the onset and progression of human disease. These models enable more efficient and effective basic, preclinical and transplant research that accelerates the conversion of science to medical solutions. Surrogen is developing pig models in these areas: Cancer, cardiovascular, congenital/heredity/neonatal, diabetes/metabolic syndrome and neurodegenerative.